RxDoctor Payments Data

Judith Alvarez, APRN

Family · Las Vegas, NVNPI 1033879770

Payments from drug & device makers

$3,320in general payments, 2019–2025

Across 98 payments — averaging $33.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Melinta Therapeutics, LLC$360
  • Gilead$318
  • Merck$165
  • Shionogi Inc$125
  • Insmed, Inc.$51
  • plus $40 from 2 others

What the payments were for

  • Food & beverage$3,320100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,320 in reported general payments places this provider in the 85th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$291,911
Medicare patients
346
Services billed
4,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala51$214,758
GenvoyaElviteg/Cob/Emtri/Tenof Alafen32$123,077
Daptomycin74$121,678
TriumeqAbacavir/Dolutegravir/Lamivudi17$72,649
DescovyEmtricitabine/Tenofov Alafenam28$61,737
StribildElviteg/Cob/Emtri/Tenofo Disop12$47,109
Cefepime Hcl52$6,732
Doxycycline Hyclate232$5,307
ErtapenemErtapenem Sodium13$4,911
Linezolid36$2,676
Rifampin66$2,549
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav129$2,343
Meropenem17$2,212
Fosfomycin Tromethamine16$1,999
Cefdinir49$1,790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy, Stribild$318$446,680123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,501 family providers in Nevada.

Other family in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →